Roles
- Associate Professor of Clinical Medicine
-
Biography
Dr. Jimenez Jimenez, who joined the Division of Transplantation and Cell Therapy in 2016, leads Sylvester’s Mismatched Allogeneic Transplant Program. His clinical and research work is dedicated to improving access to Hematopoietic Cell Transplantation (HCT) for ethnically diverse patients who lack suitable donors. A national leader in mismatched HCT, Dr. Jimenez chairs multiple trials and played a key role in establishing Sylvester’s program. He also focuses on strategies to reduce relapse risk in patients with acute leukemias and myeloid neoplasms post-transplant. -
Education & Training
Education
-
Honors & Awards
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Study Points to Broader Stem Cell Donor Options for Blood Cancer Patients
Unlocking More Matches for Stem Cell Transplants
Partial Match Parity: Increasing the Donor Pool for Hematopoietic Stem Cell Transplantation
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 7 clinical trials.
-
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML
- Principal Investigator: Antonio Jimenez
- Study Phase: Phase 3
- Enrollment Status: Closed
-
The purpose of this study is to see how well a lower dose of cyclophosphamide given after your transplant works to prevent GvHD. The study will also see if the lower dose will decrease the risk for side effects associated with the standard dose of cyclophosphamide.
- Principal Investigator: Antonio Jimenez
- Study Phase: Phase II
- Enrollment Status: Not Accepting
-
The primary objective of this study is to compare GRFS following transplantation of a PBSC product from a MMUD between standard-of-care PTCy-based GVHD prophylaxis (the control arm) and the combination of reduced-dose PTCy, abatacept, and tacrolimus.
- Principal Investigator: Antonio Jimenez
- Study Phase: Phase II
- Enrollment Status: Open
-
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
- Principal Investigator: Antonio Jimenez
- Study Phase: N/A
- Enrollment Status: Closed
-
A Multicenter Phase Ib Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Orca-T (Formerly TregGraft), a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells
- Principal Investigator: Antonio Jimenez
- Study Phase: Phase 1
- Enrollment Status: Not Accepting
-
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
- Principal Investigator: Antonio Jimenez
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The purpose of this study is to see the effects of an investigational combination treatment of venetoclax, azacitidine, and donor lymphocyte infusion (DLI) in patients with high-risk AML receiving allogeneic hematopoietic cell transplantation and to assess if the combination treatment is well tolerated and prevents disease relapse after transplant.
- Principal Investigator: Antonio Jimenez
- Study Phase: Phase I
- Enrollment Status: Closed
